Janssen’s esketamine nasal spray product, Spravato, was first approved around half a decade ago in 2019, initially indicated for use alongside an oral antidepressant for treatment-resistant depression (TRD). The next year, FDA allowed Janssen to add major depressive disorder (MDD) with acute suicidal ideation or behaviour to the product’s label (where it was again indicated for use alongside an…
